Hematuria screening

Hematuria Microchapters
Home
Patient Information
Overview
Definition
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hematuria from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hematuria screening On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hematuria screening All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hematuria screening
CDC on Hematuria screening
Hematuria screening in the news
Blogs on Hematuria screening
Directions to Hospitals Treating Hematuria
Risk calculators and risk factors for Hematuria screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Adnan Ezici, M.D[2]

Overview

There is insufficient evidence to recommend routine screening for bladder cancer in patients with hematuria.

Screening

There is insufficient evidence to recommend routine screening for bladder cancer in patients with hematuria. According to the U.S. Preventive Services Task Force (USPSTF), screening for bladder cancer in patients with hematuria is not recommended because of the insufficient evidence of benefit against harm. However, according to the recently developed scoring system, known as Haematuria Cancer Risk Score (HCRS), screening for bladder cancer in patients with hematuria with high HCRS score (based on age and sex, smoking history, and type of hematuria) might be recommended.